Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ContextLogic Inc. (LOGC)
USD8.94
-0.06 (-0.67%)
US OTC Consumer Cyclical Specialty Retail
Address
One Sansome Street 94104
San Francisco, CA, US
San Francisco, CA, US
CEO
Mark Ward
Website
wish.com
IPO
2020-12-16
CIK 2064307 ISIN US21078F1093
Also trades on
NASDAQ Global Select · WISH (USD)
Other OTC · LOGC (USD)
Description
ContextLogic Inc. functions as a global mobile-first e-commerce enterprise, with a significant presence spanning Europe, the Americas, and various other international markets. The company's primary offering is the Wish platform, a digital marketplace specifically designed to bridge the gap between consumers and a vast network of merchants. In support of these merchants, ContextLogic also provides essential marketplace infrastructure and logistical services. This San Francisco, California-based firm was initially established in 2010.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.94
-0.06 (-0.67%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
113.2K
Beta
2.03
Float Shares
27.16M
Free Float %
99.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.80% | +0.35% | -1.37% | +12.66% | +18.22% | +13.85% | +9.94% | +59.52% | +59.52% | +59.52% | +59.52% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
8.94
DCF (Levered)
0.00
-100.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-4.28
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Specialty Retail: +6.4%-100.0%
-
EPS growth Specialty Retail: +20.6%+62.7% ★ Q1'26: +237.0% (vs Q1'25)
-
FCF margin FCF growth · Specialty Retail: +29.3%— Q1'26: -63.6% (vs Q1'25)
-
EBIT margin Specialty Retail: +5.4%— Q1'26: +2.2% (vs Q1'25)
-
ROIC Specialty Retail: +6.5%— Q1'26: +0.2% (vs Q1'25)
-
Share dilution Specialty Retail: +0.1%+4.1% Q1'26: +73.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Specialty Retail: 0.14×0.00× Q1'26: -2.61× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
2.54B
est: 2.49B (+2.2%)
|
2.09B
est: 2.11B (-1.0%)
|
571.00M
est: 592.71M (-3.7%)
|
287.00M
est: 287.06M (0.0%)
|
43.00M
est: 43.00M (+0.0%)
|
—
est: 224.85M (-100.0%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EBITDA |
-619.00M
est: -1.54B (+59.9%)
|
-358.00M
est: -1.31B (+72.6%)
|
-392.00M
est: -367.69M (-6.6%)
|
-324.00M
est: -178.08M (-81.9%)
|
-78.00M
est: -15.98M (-388.1%)
|
-31.00M
est: -83.56M (+62.9%)
|
—
— – —
+100.0% YoY
|
—
— – —
|
| EBIT |
-631.00M
est: -1.55B (+59.3%)
|
-367.00M
est: -1.31B (+72.1%)
|
-398.00M
est: -370.01M (-7.6%)
|
-328.00M
est: -179.20M (-83.0%)
|
-79.00M
est: -16.11M (-390.4%)
|
-31.00M
est: -84.23M (+63.2%)
|
—
— – —
+100.0% YoY
|
—
— – —
|
| Net Income |
-745.00M
est: -3.84B (+80.6%)
|
-361.00M
est: -385.11M (+6.3%)
|
-384.00M
est: -377.18M (-1.8%)
|
-317.00M
est: -268.30M (-18.1%)
|
-75.00M
est: -63.75M (-17.6%)
|
-29.00M
est: -5.21M (-456.9%)
|
-4.46M
-4.46M – -4.46M
+14.4% YoY
|
-8.84M
-8.84M – -8.84M
-98.2% YoY
|
| SGA |
2.00B
est: 2.12B (-5.4%)
|
1.27B
est: 1.79B (-29.4%)
|
370.00M
est: 504.76M (-26.7%)
|
235.00M
est: 244.47M (-3.9%)
|
60.00M
est: 38.44M (+56.1%)
|
7.02M
est: 201.01M (-96.5%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EPS |
-175.98
est: -149.60 (-17.6%)
|
-17.10
est: -14.99 (-14.1%)
|
-17.13
est: -14.68 (-16.7%)
|
-13.36
est: -10.44 (-27.9%)
|
-2.92
est: -2.38 (-22.5%)
|
-1.09
est: -0.19 (-459.8%)
|
-0.17
-0.17 – -0.17
+14.4% YoY
|
-0.33
-0.33 – -0.33
-98.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-25.19M
OE per share TTM
-0.95
Owner's Yield
-10.95%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
2
Total invested
4.85M
Insider transactions (90d)
0
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Advisors Israel II Limited | 3.49M | 15.17% | — | 3.49M | — | 10.00 | OO | Cayman Islands | 2018-11-01 | ↗ |
| 2 | OrbiMed Israel GP II, L.P. | 3.49M | 15.17% | — | 3.49M | — | 10.00 | OO | Cayman Islands | 2018-11-01 | ↗ |
| 3 | Beryl Capital Management LLC | 3.26M | 11.00% | — | 3.26M | — | 3.26M | OO | Delaware | 2022-10-13 | ↗ |
| 4 | Beryl Capital Management LP | 3.26M | 11.00% | — | 3.26M | — | 3.26M | PN | Delaware | 2022-10-13 | ↗ |
| 5 | David A. Witkin | 3.26M | 11.00% | — | 3.26M | — | 3.26M | HC | Delaware | 2022-10-13 | ↗ |
| 6 | OrbiMed Advisors LLC | 2.98M | 12.96% | — | 2.98M | — | 10.00 | IA | Delaware | 2018-11-01 | ↗ |
| 7 | OrbiMed Capital GP VI LLC | 2.98M | 12.96% | — | 2.98M | — | 10.00 | OO | Delaware | 2018-11-01 | ↗ |
| 8 | Beryl Capital Partners II LP | 2.86M | 11.00% | — | 2.86M | — | 2.86M | PN | Delaware | 2022-10-13 | ↗ |
| 9 | Andera Partners | 1.79M | 5.62% | — | 1.79M | — | 1.79M | OO | — | 2021-02-12 | ↗ |
| 10 | BioDiscovery 5 | 1.79M | 5.62% | — | 1.79M | — | 1.79M | OO | — | 2021-02-12 | ↗ |
| 11 | Sofia Ioannidou | 1.79M | 5.62% | — | 1.79M | — | 1.79M | IN | — | 2021-02-12 | ↗ |
| 12 | Ltd. | 1.79M | 7.70% | — | 1.79M | — | 1.79M | CO | Israel | 2020-02-14 | ↗ |
| 13 | Tomer Kariv | 1.64M | 5.20% | 8.0K | 1.63M | 8.0K | 1.63M | IN | Israel | 2021-02-11 | ↗ |
| 14 | Pontifax 4 G.P., Limited Partnership | 1.63M | 5.10% | — | 1.63M | — | 1.63M | PN | Israel | 2021-02-11 | ↗ |
| 15 | Pontifax Management IV, G.P. Ltd. | 1.63M | 5.10% | — | 1.63M | — | 1.63M | CO | Israel | 2021-02-11 | ↗ |
| 16 | Ran Nussbaum | 1.63M | 5.10% | — | 1.63M | — | 1.63M | IN | Israel | 2021-02-11 | ↗ |
| 17 | Franklin Resources, Inc. | 1.60M | 5.00% | 4.00 | 4.00 | 4.00 | 4.00 | HC | Delaware | 2021-02-01 | ↗ |
| 18 | Kariv | 1.51M | 4.70% | 8.0K | 1.50M | 8.0K | 1.50M | IN | Israel | 2021-02-16 | ↗ |
| 19 | 4 G.P., Limited Partnership | 1.50M | 4.70% | — | 1.50M | — | 1.50M | PN | Israel | 2021-02-16 | ↗ |
| 20 | Management IV, G.P. Ltd. | 1.50M | 4.70% | — | 1.50M | — | 1.50M | CO | Israel | 2021-02-16 | ↗ |
| 21 | Nussbaum | 1.50M | 4.70% | — | 1.50M | — | 1.50M | IN | Israel | 2021-02-16 | ↗ |
| 22 | 13G | 1.23M | 5.80% | 12.27M | — | 12.27M | — | IN | Israel | 2019-02-12 | ↗ |
| 23 | Adage Capital Advisors, L.L.C. | 1.17M | 5.05% | — | 1.17M | — | — | OO | Delaware | 2019-05-17 | ↗ |
| 24 | Adage Capital Partners GP, L.L.C. | 1.17M | 5.05% | — | 1.17M | — | — | OO | Delaware | 2019-05-17 | ↗ |
| 25 | Adage Capital Partners, L.P. | 1.17M | 5.05% | — | 1.17M | — | — | PN | Delaware | 2019-05-17 | ↗ |
| 26 | Phillip Gross | 1.17M | 5.05% | — | 1.17M | — | — | IN | United States | 2019-05-17 | ↗ |
| 27 | Robert Atchinson | 1.17M | 5.05% | — | 1.17M | — | — | IN | United States | 2019-05-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
2
+1 vs prev Q
New positions
2
Closed positions
1
Increased
2
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CAPRICORN FUND MANAGERS LTD | — -250.0K (-100.0%) | — -1.9M (-100.0%) | 0.00% -0.937 pp | 0.00% -0.457 pp | USD— | 8 qtrs SOLD |
| 2 | YORKVILLE ADVISORS GLOBAL, LP | — -390.4K (-100.0%) | — -3.0M (-100.0%) | 0.00% -1.463 pp | 0.00% -1.864 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 426.2K | 0.25% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
18
Sells
0
Shares acquired
5.93M
Shares disposed
—
Cash buys
9.00
Cash sales
—
Net activity
+5,927,594
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Chou Jennifer K | Director | M-Exempt | A | Common Stock | 56,701 | 0.00 | — | 56,701 | D | ↗ |
| 2026-03-27 | Chevalier Chad Cordell | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-26 | LEVY PAUL S | Director | — | — | Common Stock | 0 | 0.00 | — | 500,065 | I | ↗ |
| 2026-03-17 | Bobbili Raja | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 29,000 | 8.60 | 249.4K | 350,000 | I | ↗ |
| 2026-03-16 | Bobbili Raja | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 29,271 | 8.34 | 244.1K | 321,000 | I | ↗ |
| 2026-03-13 | Bobbili Raja | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 35,229 | 8.20 | 288.9K | 291,729 | I | ↗ |
| 2026-03-12 | Bobbili Raja | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 6,500 | 8.00 | 52.0K | 256,500 | I | ↗ |
| 2026-03-10 | Bobbili Raja | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 87,366 | 7.90 | 690.2K | 250,000 | I | ↗ |
| 2026-03-09 | Bobbili Raja | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 162,634 | 7.92 | 1.29M | 162,634 | I | ↗ |
| 2026-02-26 | Bobbili Raja | Director / 10% Owner | — | — | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 16,510,740 | I | ↗ |
| 2026-02-26 | Abrams David C | Director / 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 per share | 1,758,794 | 7.00 | 12.31M | 18,269,534 | I | ↗ |
| 2026-02-26 | ABRAMS CAPITAL MANAGEMENT, L.P. | 10% Owner | — | — | Common Stock, par value $0.0001 per share | 0 | 0.00 | — | 16,510,740 | I | ↗ |
| 2026-01-15 | Heinberg Marshall S | Director | M-Exempt | A | Restricted Stock Units | 44,321 | 0.00 | — | 0 | D | ↗ |
| 2026-01-15 | Farlekas Michael | Director | A-Award | A | Restricted Stock Units | 19,206 | 0.00 | — | 19,206 | D | ↗ |
| 2026-01-15 | Chou Jennifer Kwon | Director | A-Award | A | Restricted Stock Units | 19,206 | 0.00 | — | 75,907 | D | ↗ |
| 2025-12-05 | Heinberg Marshall S | Director | M-Exempt | A | Common Stock | 64,801 | 0.00 | — | 90,485 | D | ↗ |
| 2025-12-05 | Farlekas Michael | Director | M-Exempt | A | Common Stock | 64,801 | 0.00 | — | 90,485 | D | ↗ |
| 2025-11-19 | Scarola Michael Gerard | Officer | F-InKind | D | Common Stock | 4,485 | 7.05 | 31.6K | 7,385 | D | ↗ |
| 2025-11-14 | Scarola Michael Gerard | Officer | M-Exempt | A | Common Stock | 11,870 | 0.00 | — | 11,870 | D | ↗ |
| 2025-06-30 | Scarola Michael Gerard | Officer | A-Award | A | Restricted Stock Units | 23,740 | 0.00 | — | 23,740 | D | ↗ |
| 2025-05-16 | Just Brett | Officer | F-InKind | D | Class A Common Stock | 3,301 | 7.41 | 24.5K | 29,349 | D | ↗ |
| 2025-05-15 | Just Brett | Officer | M-Exempt | D | Restricted Stock Units | 6,466 | 0.00 | — | 0 | D | ↗ |
| 2025-05-07 | Bajaj Rishi | Director / Officer | F-InKind | D | Class A Common Stock | 24,722 | 6.95 | 171.8K | 51,134 | D | ↗ |
| 2025-05-06 | Bajaj Rishi | Director / Officer | M-Exempt | A | Class A Common Stock | 55,856 | 0.00 | — | 75,856 | D | ↗ |
| 2025-04-19 | Heinberg Marshall | Director | M-Exempt | D | Restricted Stock Unit | 25,684 | 0.00 | — | 0 | D | ↗ |
| 2025-04-19 | Farlekas Michael | Director | M-Exempt | A | Class A Common Stock | 25,684 | 0.00 | — | 25,684 | D | ↗ |
| 2025-03-31 | Chou Jennifer Kwon | Director | A-Award | A | Restricted Stock Unit | 56,701 | 0.00 | — | 56,701 | D | ↗ |
| 2025-03-06 | Ward Mark Joseph | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-06 | Goldthorpe Edward J. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-18 | Just Brett | Officer | F-InKind | D | Class A Common Stock | 3,288 | 7.88 | 25.9K | 26,184 | D | ↗ |
| 2025-02-15 | Just Brett | Officer | M-Exempt | A | Class A Common Stock | 6,465 | 0.00 | — | 29,472 | D | ↗ |
| 2025-01-15 | PARISI RICHARD S | Director | A-Award | A | Restricted Stock Unit | 45,360 | 0.00 | — | 45,360 | D | ↗ |
| 2025-01-15 | LaPuma Elizabeth A. | Director | A-Award | A | Restricted Stock Unit | 20,775 | 0.00 | — | 20,775 | D | ↗ |
| 2025-01-15 | Heinberg Marshall | Director | A-Award | A | Restricted Stock Unit | 44,321 | 0.00 | — | 44,321 | D | ↗ |
| 2025-01-15 | Farlekas Michael | Director | A-Award | A | Restricted Stock Unit | 20,775 | 0.00 | — | 20,775 | D | ↗ |
| 2024-12-06 | PARISI RICHARD S | Director | A-Award | A | Restrictive Stock Unit | 64,801 | 0.00 | — | 90,485 | D | ↗ |
| 2024-12-06 | LaPuma Elizabeth A. | Director | A-Award | A | Restrictive Stock Unit | 64,801 | 0.00 | — | 90,485 | D | ↗ |
| 2024-12-06 | Heinberg Marshall | Director | A-Award | A | Restrictive Stock Unit | 64,801 | 0.00 | — | 90,485 | D | ↗ |
| 2024-12-06 | Farlekas Michael | Director | A-Award | A | Restrictive Stock Unit | 64,801 | 0.00 | — | 90,485 | D | ↗ |
| 2024-11-18 | Just Brett | Officer | F-InKind | D | Class A Common Stock | 3,317 | 6.31 | 20.9K | 23,007 | D | ↗ |
| 2024-11-15 | Just Brett | Officer | M-Exempt | A | Class A Common Stock | 6,466 | 0.00 | — | 26,324 | D | ↗ |
| 2024-08-16 | Just Brett | Officer | F-InKind | D | Class A Common Stock | 3,308 | 5.42 | 17.9K | 19,858 | — | ↗ |
| 2024-08-15 | Just Brett | Officer | M-Exempt | A | Class A Common Stock | 6,465 | 0.00 | — | 23,166 | — | ↗ |
| 2024-07-01 | Forster Joanna | Officer | F-InKind | D | Class A Common Stock | 32,635 | 5.59 | 182.5K | 59,520 | — | ↗ |
| 2024-06-28 | Forster Joanna | Officer | M-Exempt | A | Class A Common Stock | 63,063 | 0.00 | — | 92,155 | — | ↗ |
| 2022-11-16 | WYZGA MICHAEL S | Director | D-Return | D | Stock Option (right to buy) | 12,500 | 0.00 | — | 0 | — | ↗ |
| 2022-11-16 | Nacht Mariana | Officer | D-Return | D | Stock Option (right to buy) | 100,000 | 0.00 | — | 0 | — | ↗ |
| 2022-11-16 | MOSCICKI RICHARD A | Director | D-Return | D | Stock Option (right to buy) | 12,500 | 0.00 | — | 0 | — | ↗ |
| 2022-11-16 | Kay Mark A | Director | D-Return | D | Stock Option (right to buy) | 12,500 | 0.00 | — | 0 | — | ↗ |
| 2022-11-16 | Karydas Daphne | Director | D-Return | D | Stock Option (right to buy) | 12,500 | 0.00 | — | 0 | — | ↗ |
| 2022-11-16 | Kahn Susan | Director | D-Return | D | Stock Option (right to buy) | 12,500 | 0.00 | — | 0 | — | ↗ |
| 2022-11-16 | Gruskin Daniel | Officer | D-Return | D | Stock Option (right to buy) | 140,000 | 0.00 | — | 0 | — | ↗ |
| 2022-11-16 | Goater Jeff | Director | D-Return | D | Stock Option (right to buy) | 12,500 | 0.00 | — | 0 | — | ↗ |
| 2022-11-16 | Enyedy Mark J | Director | D-Return | D | Stock Option (right to buy) | 12,500 | 0.00 | — | 0 | — | ↗ |
| 2022-11-16 | Chereau Frederic | Officer | D-Return | D | Stock Option (right to buy) | 328,000 | 0.00 | — | 0 | — | ↗ |
| 2022-11-16 | Chen Leon | Director | D-Return | D | Stock Option (right to buy) | 12,500 | 0.00 | — | 0 | — | ↗ |
| 2022-06-17 | WYZGA MICHAEL S | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.00 | — | 12,500 | — | ↗ |
| 2022-06-17 | MOSCICKI RICHARD A | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.00 | — | 12,500 | — | ↗ |
| 2022-06-17 | Kay Mark A | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.38 | 4.8K | 12,500 | — | ↗ |
| 2022-06-17 | Karydas Daphne | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.00 | — | 12,500 | — | ↗ |
| 2022-06-17 | Kahn Susan | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.00 | — | 12,500 | — | ↗ |
| 2022-06-17 | Goater Jeff | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.00 | — | 12,500 | — | ↗ |
| 2022-06-17 | Enyedy Mark J | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.38 | 4.8K | 12,500 | — | ↗ |
| 2022-06-17 | Chen Leon | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 0.00 | — | 12,500 | — | ↗ |
| 2022-03-01 | Paul Andrea | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 0.70 | 56.0K | 80,000 | — | ↗ |
| 2022-03-01 | Nacht Mariana | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-03-01 | Jones Cecilia | Officer | A-Award | A | Stock Option (right to buy) | 112,000 | 0.70 | 78.4K | 112,000 | — | ↗ |
| 2022-03-01 | Gruskin Daniel | Officer | A-Award | A | Stock Option (right to buy) | 140,000 | 0.70 | 98.0K | 140,000 | — | ↗ |
| 2022-03-01 | Chereau Frederic | Director / Officer | A-Award | A | Stock Option (right to buy) | 328,000 | 0.70 | 229.6K | 328,000 | — | ↗ |
| 2022-01-12 | Jones Cecilia | Officer | F-InKind | D | Common Stock | 2,175 | 2.01 | 4.4K | 3,764 | — | ↗ |
| 2022-01-11 | Jones Cecilia | Officer | M-Exempt | A | Common Stock | 5,939 | 0.00 | — | 5,939 | — | ↗ |
| 2021-12-21 | Kahn Susan | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 2.41 | 60.3K | 25,000 | — | ↗ |
| 2021-08-09 | Gruskin Daniel | Officer | S-Sale | D | Common Stock | 1,467 | 4.35 | 6.4K | 3,331 | — | ↗ |
| 2021-08-06 | Gruskin Daniel | Officer | M-Exempt | D | Restricted Stock Units | 4,798 | 0.00 | — | 0 | — | ↗ |
| 2021-06-18 | Kay Mark A | Director | A-Award | A | Stock Option (right to buy) | 5,000 | 4.05 | 20.3K | 5,000 | — | ↗ |
| 2021-06-11 | WYZGA MICHAEL S | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 4.59 | 57.4K | 12,500 | — | ↗ |
| 2021-06-11 | MOSCICKI RICHARD A | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 4.59 | 57.4K | 12,500 | — | ↗ |
| 2021-06-11 | Kay Mark A | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 4.59 | 57.4K | 12,500 | — | ↗ |
| 2021-06-11 | Karydas Daphne | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 4.59 | 57.4K | 12,500 | — | ↗ |
| 2021-06-11 | Goater Jeff | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 4.59 | 57.4K | 12,500 | — | ↗ |
| 2021-06-11 | Enyedy Mark J | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 4.59 | 57.4K | 12,500 | — | ↗ |
| 2021-06-11 | Chen Leon | Director | A-Award | A | Stock Option (right to buy) | 12,500 | 4.59 | 57.4K | 12,500 | — | ↗ |
| 2021-05-19 | Gruskin Daniel | Officer | — | D | Employee Stock Option (Right to buy) | 85,000 | 7.92 | 673.2K | 0 | — | ↗ |
| 2021-05-17 | Paul Andrea | Officer | A-Award | A | Employee Stock Option (Right to buy) | 165,000 | 4.72 | 778.8K | 165,000 | — | ↗ |
| 2021-04-16 | Chiang Kyle | Officer | S-Sale | D | Common Stock | 2,977 | 5.73 | 17.1K | 23,387 | — | ↗ |
| 2021-04-16 | Chereau Frederic | Director / Officer | S-Sale | D | Common Stock | 7,542 | 5.73 | 43.2K | 253,811 | — | ↗ |
| 2021-04-15 | Chiang Kyle | Officer | M-Exempt | A | Common Stock | 9,360 | 0.00 | — | 26,364 | — | ↗ |
| 2021-04-15 | Chereau Frederic | Director / Officer | M-Exempt | A | Common Stock | 23,414 | 0.00 | — | 261,353 | — | ↗ |
| 2021-02-23 | Jones Cecilia | Officer | A-Award | A | Stock Option (right to buy) | 78,000 | 7.76 | 605.3K | 78,000 | — | ↗ |
| 2021-02-23 | Chiang Kyle | Officer | A-Award | A | Stock Option (right to buy) | 155,701 | 7.76 | 1.21M | 155,701 | — | ↗ |
| 2021-02-23 | Chereau Frederic | Director / Officer | A-Award | A | Stock Option (right to buy) | 282,804 | 7.76 | 2.19M | 282,804 | — | ↗ |
| 2021-01-11 | Jones Cecilia | Officer | A-Award | A | Stock Option (right to buy) | 195,000 | 8.42 | 1.64M | 195,000 | — | ↗ |
| 2021-01-01 | WYZGA MICHAEL S | Director | M-Exempt | D | Restricted Stock Units | 3,141 | 0.00 | — | 0 | — | ↗ |
| 2021-01-01 | Quick Jonathan | Director / Officer | — | D | Option to Purchase Common Stock | 15,359 | 12.75 | 195.8K | 0 | — | ↗ |
| 2021-01-01 | MOSCICKI RICHARD A | Director | M-Exempt | D | Restricted Stock Units | 3,916 | 0.00 | — | 0 | — | ↗ |
| 2021-01-01 | Kay Mark A | Director | M-Exempt | D | Restricted Stock Units | 2,199 | 0.00 | — | 0 | — | ↗ |
| 2021-01-01 | Enyedy Mark J | Director | M-Exempt | D | Restricted Stock Units | 2,921 | 0.00 | — | 0 | — | ↗ |
| 2021-01-01 | Chen Leon | Director | M-Exempt | D | Restricted Stock Units | 3,298 | 0.00 | — | 0 | — | ↗ |
| 2020-12-10 | O'Connell Daniel P | Director | M-Exempt | D | Restricted Stock Units | 2,513 | 0.00 | — | 0 | — | ↗ |
| 2020-12-10 | Karydas Daphne | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 7.36 | 147.2K | 20,000 | — | ↗ |
| 2020-12-10 | Goater Jeff | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-11-30 | Nacht Mariana | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 6.97 | 1.39M | 200,000 | — | ↗ |
| 2020-11-02 | Chiang Kyle | Officer | — | D | Option to purchase Common Stock | 23,000 | 10.10 | 232.3K | 0 | — | ↗ |
| 2020-10-01 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 639,212 | 6.00 | 3.84M | 4,126,972 | — | ↗ |
| 2020-10-01 | Chimovits Erez | Director / 10% Owner | P-Purchase | A | Common Stock | 639,212 | 6.00 | 3.84M | 4,126,972 | — | ↗ |
| 2020-09-28 | Arix Bioscience plc | 10% Owner | S-Sale | D | Common stock | 273,584 | 7.54 | 2.06M | 2,381,436 | — | ↗ |
| 2020-09-25 | Arix Bioscience plc | 10% Owner | S-Sale | D | Common stock | 174,219 | 7.08 | 1.23M | 2,655,020 | — | ↗ |
| 2020-09-24 | Arix Bioscience plc | 10% Owner | S-Sale | D | Common stock | 38,514 | 7.63 | 293.8K | 2,829,239 | — | ↗ |
| 2020-08-13 | Arix Bioscience plc | 10% Owner | S-Sale | D | Common stock | 159 | 8.75 | 1.4K | 2,867,753 | — | ↗ |
| 2020-08-12 | Arix Bioscience plc | 10% Owner | S-Sale | D | Common stock | 1,335 | 8.79 | 11.7K | 2,867,912 | — | ↗ |
| 2020-07-29 | Arix Bioscience plc | 10% Owner | S-Sale | D | Common stock | 2,709 | 8.78 | 23.8K | 2,869,247 | — | ↗ |
| 2020-07-22 | Arix Bioscience plc | 10% Owner | S-Sale | D | Common stock | 22,651 | 9.00 | 203.9K | 2,871,956 | — | ↗ |
| 2020-07-20 | Arix Bioscience plc | 10% Owner | S-Sale | D | Common stock | 36,983 | 9.25 | 342.1K | 2,894,607 | — | ↗ |
| 2020-07-17 | Arix Bioscience plc | 10% Owner | S-Sale | D | Common stock | 31,101 | 9.24 | 287.4K | 2,931,590 | — | ↗ |
| 2020-07-16 | Arix Bioscience plc | 10% Owner | S-Sale | D | Common stock | 16,332 | 8.56 | 139.8K | 2,962,691 | — | ↗ |
| 2020-06-19 | WYZGA MICHAEL S | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 7.96 | 79.6K | 10,000 | — | ↗ |
| 2020-06-19 | O'Connell Daniel P | Director | A-Award | A | Restricted Stock Units | 2,513 | 0.00 | — | 2,513 | — | ↗ |
| 2020-06-19 | MOSCICKI RICHARD A | Director | A-Award | A | Restricted Stock Units | 3,916 | 0.00 | — | 3,916 | — | ↗ |
| 2020-06-19 | Kay Mark A | Director | A-Award | A | Restricted Stock Units | 2,199 | 0.00 | — | 2,199 | — | ↗ |
| 2020-06-19 | Enyedy Mark J | Director | A-Award | A | Restricted Stock Units | 2,921 | 0.00 | — | 2,921 | — | ↗ |
| 2020-06-19 | Chimovits Erez | Director | A-Award | A | Restricted Stock Units | 2,513 | 0.00 | — | 2,513 | — | ↗ |
| 2020-06-19 | Chen Leon | Director | A-Award | A | Restricted Stock Units | 3,298 | 0.00 | — | 3,298 | — | ↗ |
| 2020-04-15 | Yoon Seokho Bryan | Officer | A-Award | A | Restricted Stock Units | 17,445 | 0.00 | — | 17,445 | — | ↗ |
| 2020-04-15 | Jaffe Matthias | Officer | A-Award | A | Restricted Stock Units | 17,218 | 0.00 | — | 17,218 | — | ↗ |
| 2020-04-15 | Chereau Frederic | Director / Officer | A-Award | A | Restricted Stock Units | 23,414 | 0.00 | — | 23,414 | — | ↗ |
| 2020-03-17 | Enyedy Mark J | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 5.34 | 106.8K | 20,000 | — | ↗ |
| 2020-02-11 | Yoon Seokho Bryan | Officer | A-Award | A | Stock Option (right to buy) | 95,000 | 7.11 | 675.5K | 95,000 | — | ↗ |
| 2020-02-11 | Jaffe Matthias | Officer | A-Award | A | Stock Option (right to buy) | 69,000 | 7.11 | 490.6K | 69,000 | — | ↗ |
| 2020-02-11 | Huttner Kenneth | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 7.11 | 355.5K | 50,000 | — | ↗ |
| 2020-02-11 | Chereau Frederic | Director / Officer | A-Award | A | Stock Option (right to buy) | 222,000 | 7.11 | 1.58M | 222,000 | — | ↗ |
| 2019-12-19 | WYZGA MICHAEL S | Director | A-Award | A | Stock Option (right to buy) | 10,869 | 12.65 | 137.5K | 10,869 | — | ↗ |
| 2019-12-19 | O'Connell Daniel P | Director | A-Award | A | Stock Option (right to buy) | 10,869 | 12.65 | 137.5K | 10,869 | — | ↗ |
| 2019-12-19 | MOSCICKI RICHARD A | Director | A-Award | A | Stock Option (right to buy) | 10,869 | 12.65 | 137.5K | 10,869 | — | ↗ |
| 2019-12-19 | Kay Mark A | Director | A-Award | A | Stock Option (right to buy) | 10,869 | 12.65 | 137.5K | 10,869 | — | ↗ |
| 2019-12-19 | Kariv Tomer | Director | A-Award | A | Stock Option (right to buy) | 10,869 | 12.65 | 137.5K | 10,869 | — | ↗ |
| 2019-12-19 | Chimovits Erez | Director | A-Award | A | Stock Option (right to buy) | 10,869 | 12.65 | 137.5K | 10,869 | — | ↗ |
| 2019-12-19 | Chen Leon | Director | A-Award | A | Stock Option (right to buy) | 10,869 | 12.65 | 137.5K | 10,869 | — | ↗ |
| 2019-12-11 | Yoon Seokho Bryan | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 8.20 | 902.0K | 110,000 | — | ↗ |
| 2019-11-11 | Yoon Seokho Bryan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-08-27 | Wilton Thomas | Officer | M-Exempt | A | Employee Stock Option (right to buy) | 75,000 | 0.73 | 54.8K | 139,108 | — | ↗ |
| 2019-02-20 | Huttner Kenneth | Officer | A-Award | A | Stock Option (right to buy) | 50,818 | 9.06 | 460.4K | 50,818 | — | ↗ |
| 2018-10-23 | ORBIMED ADVISORS LLC | Director / 10% Owner | C-Conversion | A | Common Stock | 2,279,023 | 0.00 | — | 5,276,783 | — | ↗ |
| 2018-10-23 | O'Connell Daniel P | Director | C-Conversion | A | Common Stock | 2,279,023 | 0.00 | — | 2,279,023 | — | ↗ |
| 2018-10-23 | Kariv Tomer | Director | C-Conversion | A | Common Stock | 674,431 | 0.00 | — | 674,431 | — | ↗ |
| 2018-10-23 | Ioannidou Sofia | Director | P-Purchase | A | Common Stock | 420,000 | 10.00 | 4.20M | 1,787,413 | — | ↗ |
| 2018-10-23 | Chimovits Erez | Director | P-Purchase | A | Common Stock | 490,000 | 10.00 | 4.90M | 3,487,760 | — | ↗ |
| 2018-10-23 | Arix Bioscience plc | 10% Owner | P-Purchase | A | Common stock | 700,000 | 10.00 | 7.00M | 2,979,023 | — | ↗ |
| 2018-10-18 | Wilton Thomas | Officer | — | D | Option to Purchase Common Stock | 214,108 | 0.73 | 156.3K | 0 | — | ↗ |
| 2018-10-18 | WYZGA MICHAEL S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-10-18 | Poole Sandra | Officer | — | D | Option to Purchase Common Stock | 256,930 | 0.73 | 187.6K | 0 | — | ↗ |
| 2018-10-18 | ORBIMED ADVISORS LLC | Director / 10% Owner | — | I | Series A Convertible Preferred Stock | 1,402,444 | 0.00 | — | 0 | — | ↗ |
| 2018-10-18 | O'Connell Daniel P | Director | — | I | Series B Convertible Preferred Stock | 2,279,023 | 0.00 | — | 0 | — | ↗ |
| 2018-10-18 | MOSCICKI RICHARD A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-10-18 | Kay Mark A | Director | — | D | Common Stock | 0 | 0.00 | — | 776,794 | — | ↗ |
| 2018-10-18 | Kariv Tomer | Director | — | I | Series B Convertible Preferred Stock | 328,339 | 0.00 | — | 0 | — | ↗ |
| 2018-10-18 | Jaffe Matthias | Officer | — | D | Common Stock | 0 | 0.00 | — | 214,108 | — | ↗ |
| 2018-10-18 | Ioannidou Sofia | Director | — | I | Series B Convertible Preferred Stock | 1,367,413 | 0.00 | — | 0 | — | ↗ |
| 2018-10-18 | Falb Dean | Officer | — | D | Option to Purchase Common Stock | 214,108 | 0.73 | 156.3K | 0 | — | ↗ |
| 2018-10-18 | Chimovits Erez | Director | — | I | Series B Convertible Preferred Stock | 1,595,316 | 0.00 | — | 0 | — | ↗ |
| 2018-10-18 | Chereau Frederic | Director / Officer | — | D | Option to Purchase Common Stock | 547,000 | 0.73 | 399.3K | 0 | — | ↗ |
| 2018-10-18 | Chen Leon | Director | — | D | Common Stock | 0 | 0.00 | — | 19,035 | — | ↗ |
| 2018-10-18 | Arix Bioscience plc | 10% Owner | — | I | Series B Convertible Preferred Stock | 2,279,023 | 0.00 | — | 0 | — | ↗ |
| 2006-03-09 | MORRISON ALBERT JR | Director | A-Award | A | Director Option to Buy | 15,000 | 1.16 | 17.4K | 100,000 | — | ↗ |
| 2005-07-11 | KANTER JOEL S | Director | S-Sale | D | LOGIC Devices Incorporated Common Stock | 5,200 | 1.28 | 6.7K | 4,500 | — | ↗ |
| 2005-07-01 | KANTER JOEL S | Director | S-Sale | D | LOGIC Devices Incorporated Common Stock | 300 | 1.30 | 390.00 | 9,700 | — | ↗ |
| 2005-03-10 | MORRISON ALBERT JR | Director | A-Award | A | Director Option to Buy | 15,000 | 1.46 | 21.9K | 105,000 | — | ↗ |
| 2005-03-10 | KANTER JOEL S | Director | A-Award | A | Director Option to Buy | 15,000 | 1.46 | 21.9K | 40,000 | — | ↗ |
| 2005-02-01 | KANTER JOEL S | Director | M-Exempt | A | LOGIC Devices Incorporated common stock | 10,000 | 1.10 | 11.0K | 10,000 | — | ↗ |
| 2005-01-25 | KANTER JOEL S | Director | S-Sale | D | LOGIC Devices Incorporated common stock | 3,202 | 1.45 | 4.6K | 0 | — | ↗ |
| 2005-01-21 | KANTER JOEL S | Director | S-Sale | D | LOGIC Devices Incorporated | 5,798 | 1.45 | 8.4K | 3,202 | — | ↗ |
| 2004-03-18 | MORRISON ALBERT JR | Director | A-Award | A | Option to buy | 15,000 | 1.70 | 25.5K | 100,000 | — | ↗ |
| 2004-03-18 | KANTER JOEL S | Director | A-Award | A | Option to Buy | 15,000 | 1.70 | 25.5K | 35,000 | — | ↗ |
| 2004-01-18 | KANTER JOEL S | Director | S-Sale | D | LOGIC Devices Incorporated common stock | 1,000 | 1.45 | 1.5K | 9,000 | — | ↗ |
| 2003-12-02 | KANTER JOEL S | Director | M-Exempt | D | Director Stock Option (Right to Buy) | 10,000 | 1.10 | 11.0K | 20,000 | — | ↗ |
| 2003-11-13 | KANTER JOEL S | Director | S-Sale | D | LOGIC Devices Incorporated Common Stock | 3,200 | 2.31 | 7.4K | 0 | — | ↗ |
| 2003-11-12 | KANTER JOEL S | Director | S-Sale | D | LOGIC Devices Incorporated Common Stock | 900 | 2.30 | 2.1K | 9,000 | — | ↗ |
| 2003-10-27 | KANTER JOEL S | Director | S-Sale | D | LOGIC Devices Incorporated Common Stock | 2,021 | 2.20 | 4.4K | 10,000 | — | ↗ |
| 2003-10-24 | KANTER JOEL S | Director | M-Exempt | D | Director Stock Option (Right to Buy) | 10,000 | 1.10 | 11.0K | 30,000 | — | ↗ |
| 2003-10-23 | KANTER JOEL S | Director | S-Sale | D | LOGIC Devices Incorporated Common Stock | 3,479 | 2.24 | 7.8K | 12,521 | — | ↗ |
| 2003-10-21 | KANTER JOEL S | Director | S-Sale | D | LOGIC Devices Incorporated Common Stock | 1,000 | 2.43 | 2.4K | 6,000 | — | ↗ |
| 2003-09-25 | SCHAEFER GARY C | Officer | A-Award | A | Incentive Stock Option | 50,000 | 1.40 | 70.0K | 50,000 | — | ↗ |
| 2003-08-29 | SCHAEFER GARY C | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-06-24 | KANTER JOEL S | Director | M-Exempt | D | Director Stock Option (Right to Buy) | 10,000 | 1.10 | 11.0K | 40,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
27.31M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Rishi Bajaj Former Chief Executive Officer | 516.7K | 825.0K | 6.40M | — | — | 15.2K | 7.75M | 82.50% | ↗ |
| 2 | 2025 | Brett Just Former Chief Financial Officer | 275.0K | 112.5K | — | — | — | 296.8K | 684.3K | 0.00% | ↗ |
| 3 | 2025 | Michael Scarola Former Chief Financial Officer | 237.7K | — | 161.7K | — | — | 108.00 | 399.5K | 40.47% | ↗ |
| 4 | 2021 | Frederic Chereau President and Chief Executive Officer | 542.5K | 244.9K | — | 1.44M | — | 5.8K | 2.23M | 64.40% | ↗ |
| 5 | 2021 | Cecilia Jones Chief Financial Officer and Treasurer | 366.6K | 148.4K | 50.0K | 1.47M | — | 5.8K | 2.04M | 74.51% | ↗ |
| 6 | 2021 | Daniel Gruskin Chief Medical Officer | 414.1K | 157.6K | — | 961.5K | — | 5.8K | 1.54M | 62.48% | ↗ |
| 7 | 2020 | Frederic Chereau President and Chief Executive Officer | 479.3K | 192.2K | 120.8K | 1.06M | — | 5.7K | 1.86M | 63.54% | ↗ |
| 8 | 2020 | Mariana Nacht, Ph.D. Chief Scientific Officer | 35.7K | — | — | 909.8K | — | 716.00 | 946.3K | 96.15% | ↗ |
| 9 | 2020 | Bryan Yoon Former Chief Administrative Officer, General Counsel and Corporate Secretary | 299.2K | — | 90.0K | 453.4K | — | 25.5K | 868.1K | 62.60% | ↗ |
| 10 | 2020 | Kyle Chiang, Ph.D. Chief Operating Officer | 273.3K | 69.8K | 48.3K | 451.1K | — | 5.7K | 848.2K | 58.87% | ↗ |
| 11 | 2019 | Kenneth Huttner, M.D., Ph.D. Senior Vice President, Head of Clinical Development | 300.0K | 59.9K | — | 299.3K | — | 105.6K | 764.8K | 39.14% | ↗ |
| 12 | 2019 | Bryan Yoon, Esq. Chief Administrative Officer, General Counsel and Corporate Secretary | 54.8K | 10.9K | — | 591.9K | — | 8.1K | 665.7K | 88.91% | ↗ |
| 13 | 2019 | Bryan Yoon Former Chief Administrative Officer, General Counsel and Corporate Secretary | 54.8K | 10.9K | — | 591.9K | — | 8.1K | 665.7K | 88.91% | ↗ |
| 14 | 2019 | Frederic Chereau President and Chief Executive Officer | 510.0K | 117.3K | — | — | — | 5.6K | 632.9K | 0.00% | ↗ |
| 15 | 2018 | Sandra Poole Former Chief Operating Officer | 244.1K | 68.2K | — | 1.83M | — | 4.9K | 2.14M | 85.19% | ↗ |
| 16 | 2018 | Frederic Chereau President and Chief Executive Officer | 411.4K | 174.0K | — | 1.01M | — | 5.5K | 1.60M | 63.07% | ↗ |
| 17 | 2018 | Dean Falb, Ph.D. Chief Scientific Officer | 206.0K | 58.2K | — | 1.30M | — | 4.1K | 1.56M | 82.85% | ↗ |
| 18 | 2017 | Frederic Chereau President and Chief Executive Officer | 385.0K | 154.0K | — | 240.3K | — | — | 779.3K | 30.83% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chad Chevalier | Interim Chief Financial Officer | — | male |
| Janak Goyani | Vice President of Investments | — | male |
| Mark Ward | President & Director | — | male |
| Matthew Worby | Chief Human Resources Officer | — | male |
| Sheng Zhang | Co-Founder | — | male |
| Shuyan Wang | Head of Data Science | — | female |
ESG Rating
ESG Score History SPECIALTY RETAIL
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LOGC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
